Cliënt tijdens consult medisch afvallen traject bij The Body Clinic

Retatrutide

Achieve your weight goals with the power of Retatrutide

Nicolette Lammers
none provided
The information on this page has been medically reviewed by
Make an appointment

What is Retatrutide?

Retatrutide, often referred to online as "reta" for short, is a new weight loss drug from Eli Lilly that is still under investigation. It is a weekly injection that simultaneously acts on three hormone receptors: GLP-1, GIP, and glucagon. Mounjaro works on two of these and Wegovy on one. The initial results from the large phase 3 studies are very promising. In the largest study, participants on the highest dose lost an average of 28.3% of their body weight after 80 weeks.

*Retatrutide is not yet approved anywhere in the world.

Buying Retatrutide

Because retatrutide is currently in the research phase, it cannot yet be purchased. It is expected that, like other weight loss medications, it will be a prescription-only drug, meaning it will only be available with a doctor's prescription. In the Netherlands, this is not expected before the end of 2027. If retatrutide is offered online now, it is always an illegal and uncontrolled product. Read more about the risks of illegally purchased weight loss medication. The Body Clinic does not sell or mediate retatrutide.

Is it safe to buy retatrutide? What the NVIC, Radar and the inspectorate say

No. Retatrutide has not been approved anywhere in the world. Anything you can buy online or through social media right now is illegal and unregulated. That means you don't know what is in the vial, how strong it is or whether it was made under clean conditions.

The inspectorate: life-threatening The Dutch Health and Youth Care Inspectorate (IGJ) calls the use of these products life-threatening. Sellers often state that the product is intended for laboratory research only. According to the IGJ, this does not make the sale legal: if it is clear that the product is meant to be injected, selling it remains prohibited. Read the IGJ's response (in Dutch).

The NVIC: more and more poisonings In 2025, the Dutch Poisons Information Centre (NVIC) received six reports of poisoning by retatrutide. In 2026, there have already been more than ten times as many. The reported symptoms include nausea, vomiting, heart palpitations, dizziness and dehydration. Read the NVIC's report (in Dutch).

Radar: even children can order it On 26 October 2026, the Dutch consumer programme Radar showed how easy it is: a 14-year-old was able to order retatrutide online without any problems. Watch the Radar broadcast (in Dutch).

Have you used retatrutide and are you experiencing symptoms? Contact your GP.

Retatrutide Price

No price is known yet. A price will only be set after a drug is approved, and it may vary per country. Please note: any price you see online now always belongs to an illegal product.

Products:Retatrutide
Pharmacist:Eli Lilly
Active ingredient:Retatrutide
Treatment type:Obesity and type 2 diabetes
Dosage:-
Administration:Once a week
Approval phase:Research phase
Side effects:No overview of possible side effects known yet

Who is Retatrutide Peptide suitable for?

The studies included adults with a BMI (Body Mass Index) of: 30 or higher (obesity) or 27 to 30 (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, high cholesterol, osteoarthritis, or sleep apnea. The target group for retatrutide will be determined once the medication is approved.

Retatrutide Prescription

Retatrutide is only available by prescription from a doctor if the patient meets the indications described above. However, the research phase still needs to be completed, and it is currently unclear if and when it will enter the Dutch market.

How Retatrutide Works

Retatrutide acts on three hormone receptors simultaneously: GLP-1, GIP, and glucagon. Together, they help reduce appetite, promote a feeling of fullness more quickly, regulate blood sugar, and stimulate fat burning.

Side effects and safety of retatrutide

Retatrutide has not yet been approved by the U.S. FDA or the European EMA. What we currently know about side effects comes from Phase 3 studies. In the TRIUMPH-2 study (published in The Lancet, September 2026), which involved 1,152 adults with obesity and type 2 diabetes, gastrointestinal symptoms were the most common, such as diarrhea (up to 34%) and nausea (up to 28%). At the highest dose, 7.7% of participants discontinued treatment due to side effects, compared with 4.9% in the placebo group.

A lesser-known side effect is dysesthesia: an unusual sensation in the skin, such as tingling, burning, or prickling. This occurred in 4.5 to 7.3% of participants, compared with 0.7% in the placebo group. Whether retatrutide is safe for long-term use will not be assessed until the application for approval is submitted.

Retatrutide and sleep apnea: what does the research say?

Retatrutide has also been studied in people with moderate to severe obstructive sleep apnea and overweight. In the TRIUMPH-OSA studies, published in the New England Journal of Medicine (October 2026), over 690 participants were followed for 80 weeks.

The key findings:

  • Fewer breathing pauses: in participants without diabetes, the number of breathing pauses per hour fell by 34.3 on 9 mg of retatrutide, compared with 9.9 on placebo.
  • Weight loss: participants lost between 12.5% and 22.2% of their body weight, depending on the dose and study group.

Retatrutide is still in phase 3 of clinical trials and has not yet been approved as a medicine. It is therefore not yet available in the Netherlands. For the time being, people with sleep apnea will have to rely on current treatments, such as CPAP.

Want to know more? Read our blog about retatrutide and sleep apnea.

Retatrutide for osteoarthritis: what does the research say?

Following sleep apnoea, retatrutide has also been investigated in people who are overweight and suffer from knee pain due to osteoarthritis, in two phase 3 studies. In TRIUMPH-4 (445 participants, 68 weeks), the pain score (WOMAC, scale 0–10) fell by 3.7 to 4.0 points, compared with 2.1 points for the placebo. In TRIUMPH-1 (574 participants with osteoarthritis, 80 weeks), the reduction was 3.2 to 3.6 points, compared with 1.9 points in the placebo group. Around two-thirds of participants receiving retatrutide experienced at least a 50 per cent reduction in knee pain, compared with 38 per cent in the placebo group. In TRIUMPH-4, participants lost 20 to 24 per cent of their body weight, compared with 4.6 per cent in the placebo group. Serious side effects were more common with retatrutide, particularly gastrointestinal symptoms.

The results were published in November 2026 in The New England Journal of Medicine (Schnitzer et al., doi: 10.1056/NEJMoa2610676). Retatrutide has not yet been approved for any indication; these results do not indicate its availability.

Retatrutide or Ozempic: what does the research say?

In the TRANSCEND-T2D-2 study, retatrutide was compared directly with another weight loss and diabetes medication for the first time: Ozempic (semaglutide). The study included people with type 2 diabetes, who were followed for 80 weeks.

The results according to manufacturer Eli Lilly:

  • Weight: participants on retatrutide lost 19.5% (9 mg) to 20.9% (12 mg) of their body weight, compared with 9.4% on Ozempic 2 mg.
  • Blood sugar: HbA1c fell by 2.2 percentage points with retatrutide, compared with 1.8 with Ozempic.
  • Side effects: 4.8% (9 mg) and 7.9% (12 mg) of participants stopped retatrutide because of side effects, compared with 2.7% on Ozempic.

Keep in mind:

  • These figures come from an Eli Lilly press release (28 October 2026). The full results have not yet been published in a scientific journal.
  • Participants knew which medication they were receiving (open-label study).
  • Retatrutide was compared with the diabetes dose of Ozempic, not with Wegovy or Mounjaro. A direct comparison with Mounjaro is still ongoing.
  • Retatrutide has not been approved anywhere and is not available in the Netherlands.

The difference between Retatrutide and Tirzepatide

Tirzepatide has a dual mechanism of action, while retatrutide has a triple mechanism of action.

Person self-injecting insulin into their abdomen with a medical pen.

Switching to Retatrutide: is it possible yet?

No. As long as retatrutide has not been approved, no one can switch you to it, not even if you are already using Wegovy or Mounjaro. Therefore, do not stop your current medication: those who stop a GLP-1 agent often regain a large part of the lost weight. Also, do not switch via a webshop, because you don't know what you are injecting there. How a safe transition will proceed will only become clear after approval. You will then make that decision together with your treating physician.

Retatrutide Reimbursement by the Health Insurer

The drug retatrutide has not yet been approved by the FDA and the Ministry of Public Health. Therefore, it is not yet possible to say whether it will be reimbursed in the future.

Retatrutide Dosage

In the phase 3 studies, participants received 4, 9, or 12 mg once a week. The dose was built up step by step. Which dosages will become available depends on the approval.

Where to Inject Retatrutide?

Retatrutide is administered via a subcutaneous injection. Do not inject it into a vein or muscle. The best places to inject are:

  • in the thigh
  • in the lower abdomen
  • in the upper arm
  • Reta is the abbreviation many people use online for retatrutide, Eli Lilly's experimental weight-loss drug. It is not yet approved and not legally available.

  • In the largest study, participants on the highest dose lost an average of 28.3% of their body weight after 80 weeks. For people with type 2 diabetes, this was less, up to 20.8%.

  • During the 3-phase study, mainly gastrointestinal complaints such as nausea, diarrhea, and constipation occurred. Additionally, skin tingling (dysesthesia) and slightly more frequent urinary tract infections were reported. Most complaints were mild to moderate.

  • Not yet. Lilly plans to submit the application in the US in the first quarter of 2027, with Europe following afterwards. Retatrutide is not expected to be available in the Netherlands before the end of 2027.

  • Not yet, as retatrutide has not been approved by the FDA and the Ministry of Health. Do not stop your current medication and discuss a potential switch with your doctor after approval.

  • No. Reta 3 is a capsule supplement without retatrutide. Illegal webshops sometimes also use the name for uncontrolled powder. Retatrutide itself is not approved anywhere.

  • No. Reta 3, RetaFit and GLP3-B are capsule supplements that do not contain retatrutide. They are sold online under names that deliberately resemble those of the medicinal product. Retatrutide itself is an injection produced by Eli Lilly that is still being researched and has not been approved anywhere.

  • The correct spelling is retatrutide. Retatutride and retratrutide are misspellings. 'R3ta' is an abbreviation mainly used in illegal online sales. Retatrutide has not yet been approved anywhere, so what is offered online has not been verified. Read more in our blog about retatrutide.

  • No. Retatrutide has not yet been approved anywhere in the world; Lilly intends to submit its application to the US FDA in the first quarter of 2027, and approval in Europe will only follow after that. Anything currently on sale online is illegal and falls under the warning issued by the Health and Youth Care Inspectorate (IGJ), which describes its use as life-threatening.